Clofarabine in High Risk Myelodysplastic Syndrome (MDS)
Status:
Completed
Trial end date:
2014-03-01
Target enrollment:
Participant gender:
Summary
This study aims to determine the maximal tolerated dose (MTD) and dose limiting toxicities
(DLTs) of low dose IV clofarabine for MDS patients after treatment failure of azacitidine.